Leprosy in transplant recipients: Report of a case after liver transplantation and review of the literature

Transplant Infectious Disease

Volumn 13, Issue 1, 2011, Pages 63-69

  Trindade, M A B ^a,b   Palermo, M L ^c   Pagliari, C ^a   Valente, N ^a   Naafs, B ^d   Massarollo, P C B ^e   D'Albuquerque, L A C ^f   Benard, G ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto de Saude de Sao Paulo   (Brazil)

^c Laboratory of Medical Investigation Unit 56   (Brazil)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^f HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

Author keywords

Immunosuppression; Leprosy; Liver transplant; Mycobacterium leprae

Indexed keywords

CLOFAZIMINE; DAPSONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RIFAMPICIN; TACROLIMUS;

ACID FAST BACTERIUM; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BACTERIUM ISOLATION; CASE REPORT; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEPROMATOUS LEPROSY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MACROPHAGE; MALE; MULTIBACILLARY LEPROSY; NEURITIS; ORGAN DONOR; PAPULE; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SKIN BIOPSY; SKIN GRANULOMA; STAINING;

EID: 79551680392     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00549.x     Document Type: Article

References (25)

1. WHO. Global Leprosy Situation 2009. Wkly Epidemiol Rec 2009; 33: 333-340.
2. Qin MH, Madiraju MV, Rajagopalan M. Characterization of the functional replication origin of Mycobacterium tuberculosis. Gene 1999; 233: 121-130.
3. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004; 363: 1209-1217.
4. Naafs B, Wheate HW. The time interval between the start of anti-leprosy treatment and the development of reactions in borderline patients. Lepr Rev 1978; 49: 153-157.
5. Moura AK, Melo BL, Brito AE, et al. High levels of liver enzymes in five patients with type 1 leprosy reaction. Eur Acad Dermatol Venereol 2009; 23: 96-98.
6. Pereira GA, Stefani MM, Araújo Filho JA, Souza LC, Stefani GP, Martelli CM. Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium leprae co-infection: HIV-1 subtypes and clinical, immunologic, and histopathologic profiles in a Brazilian cohort. Am J Trop Med Hyg 2004; 71: 679-684.
7. Hussain T, Sinha S, Kulshreshtha KK, et al. Seroprevalence of HIV infection among leprosy patients in Agra, India: trends and perspective. Int J Lepr Other Mycobact Dis 2005; 73: 93-99.
8. Date A, John GT, Thomas PP, Jacob CK. Leprosy and renal transplantation. Lepr Rev 1998; 69 (1): 40-45.
9. Roselino AM, de Almeida AM, Foss NT, et al. Renal transplantation in leprosy patients. Int J Lepr Other Mycobact Dis 1993; 61: 102-105.
10. Shih HC, Hung TW, Lian JD, Tsao SM, Hsieh NK, Yang JH. Leprosy in a renal transplant recipient: a case report and literature review. J Dermatol 2005; 32 (8): 661-666.
11. Mushatt DM, Wattanamano P, Alvarado FS. Lepromatous leprosy in a renal transplant recipient. Clin Infect Dis 1998; 26: 217-218.
12. Agarwal DK, Mehta AR, Sharma AP, et al. Coinfection with leprosy and tuberculosis in a renal transplant recipient. Nephrol Dial Transplant 2000; 15: 1720-1721.
13. Guditi S, Ram R, Ismal KM, et al. Leprosy in a renal transplant recipient: review of the literature. Transpl Infect Dis 2009; 11 (6): 557-562. [Epub ahead of print July 28].
14. Gasink LB, Seymour C, Blumberg EA, Goldberg LR, Fishman NO. An uncommon presentation of an uncommon disease: leprosy in a heart transplant recipient. J Heart Lung Transplant 2006; 25: 854-856.
15. Modi K, Mancini M, Joyce MP. Lepromatous leprosy in a heart transplant recipient. Am J Transplant 2003; 3: 1600-1603.
16. Launius BK, Brown PA, Cush E, Mancini MC. A case study in Hansen's disease acquired after heart transplant. Crit Care Nurs Q 2004; 27: 87-91.
17. Batista MD, Porro AM, Maeda SM, et al. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis 2008; 46: 56-60.
18. Pieroni F, Stracieri ABPL, Moraes DA, et al. Six cases of leprosy associated with allogeneic hematopoietic SCT. Bone Marrow Transplant 2007; 40: 859-863.
19. Sampaio EP, Caneshi JR, Nery JA, et al. Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. Infect Immun 1995; 63: 1848-1854.
20. Walker SL, Lockwood DN. The clinical and immunological features of leprosy. Br Med Bull 2006; 77-78: 103-121.
21. Janeway C, Travers P, Walport M, Capra JD. The manipulation of the immune response. In Murphy K, Travers P, Walport M (eds): Janeway's Immunobiology, 7th edn. London, UK: Garland Science, Taylor & Francis Group Publishing, New York, 2008: 656-659.
22. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
23. Safa G, Darrieux L, Coic A, Tisseau L. Type 1 leprosy reversal reaction treated with topical tacrolimus along with systemic corticosteroids. Indian J Med Sci 2009; 63: 359-362.
24. Burdick AE, Ramirez CC. The role of mycophenolate mofetil in the treatment of leprosy reactions. Int J Lepr Other Mycobact Dis 2005; 73: 127-128.
25. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.